Stents

Flexible Stenting Solutions Inc. has submitted an Investigational Device Exemption application to the FDA for its FlexStent® Femoropopliteal SE Stent System for the treatment of peripheral artery disease in the superficial femoral and popliteal arteries.

Medical device pioneer Stentys announced today that it has extended its ‘self-expanding’ and ‘disconnectable’ technology platform to include a second major indication—acute myocardial infarction.

A comprehensive analysis published today in The Lancet from the ABSORB clinical trial demonstrated that Abbott’s bioabsorbable drug eluting stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years.

VOYAGER™ NC Coronary Balloon Catheter is the latest Innovation in Balloon Technology, Designed to Optimize Treatment of Patients with Coronary Artery Disease

Micrus Endovascular Corporation (Nasdaq:MEND) today announced it has enrolled the first patient in the Vitesse Intracranial Stent Study for Ischemic Therapy (VISSIT)

Flexible Stenting Solutions, Inc., a leading developer of next-generation flexible stents, announced today it has received CE Mark for its FlexStent™ Biliary Self Expanding Stent System.

The CYPHER SELECT®Plus Sirolimus-eluting Coronary Stent has received CE marking within the European Union for treatment of patients with diabetes, a complex and often difficult-to-treat patient population.

Micrus Endovascular Corporation today announced it has enrolled the first patient in the Vitesse Intracranial Stent Study for Ischemic Therapy (VISSIT).

Boston Scientific Corporation (NYSE: BSX) announced the beginning of patient enrollment in the PLATINUM clinical trial, which is designed to evaluate the Company’s PROMUS™ Element™ Everolimus-Eluting Coronary Stent.

Innovative Medical Device Extends Possibility of Minimally Invasive Endovascular Repair of Aortic Aneurysms to More Patients

Flexible Stenting Solutions, Inc., a leading developer of next-generation flexible stents, announced today it has received CE Mark for its FlexStent™ Femoropopliteal Self Expanding Stent System.

Isotechnika Inc. announced today that its partner, Atrium Medical Corporation has completed patient enrollment for their CONFIRM 1, First-in-Man (FIM) drug coated coronary stent clinical trial evaluating Atrium’s CINATRATM voclosporin coated coronary stent system.

Study reports excellent long-term durability of the St. Jude Medical Biocor™ Stented Tissue Valve for mitral and aortic valve replacement

Allium Group announced today that it has been awarded CE mark for its prostatic stent enabling commercialization of the system in the European Union and the countries that recognize the CE Mark.

Boston Scientific Corporation has announced a decision by the United States District Court in Delaware regarding a patent owned by Johnson & Johnson and Boston Scientific’s NIR® stent product

Three patients with established cardiac ischemia recently became the first recipients of the vProtect Luminal Shield